| |
|
|
urology Research projects
Wayne Hellstrom, M.D., F.A.C.S.
1. ERECTILE FUNCTION IN NON-INVASIVE HYPERACTIVE BLADDER MODEL
(submitted research protocol to IACUC)
2. EFFECTS OF SILDENAFIL TREATMENT ON ERECTILE FUNCTION FROM RATS MADE HYPERTENSIVE BY NITRIC OXIDE INHIBITION
(ongoing research)
Oliver Sartor, M.D.
1. The association between prenatal Testosterone and Prostate Cancer Risk using an anthropometric marker derived from measuring the lengths of the fingers, the ratio of index-finger to ring-finger length (2D:4D), for men with and without prostate cancer over the age of 50.
Open for enrollment. Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
2. COU-AA-301 A phase 3, randomized double-blind, placebo-controlled study of abiraterone acetate (CB7630) plus prednisone in patients with metastatic castration-resistant prostate cancer who have failed docetaxel-based chemotherapy. (COUGAR).
Enrollment pending. For metastatic castration-resistant prostate cancer after taxotere. Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
3.
AVO108943 A randomized double-blind parallel group study comparing Casodex 50 mg. plus placebo to Casodex 50mg plus dutasteride 3.5mg administered for 18 months to men with prostate cancer who have failed first-line androgen deprivation therapy (assessed by rising PSA) followed by a two-year extension. (TARP) Glaxo-Smith Kline.
Enrollment pending. For rising PSA non-metastatic prostate cancer, (no prior Casodex). Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
4. XRP6258- A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen (TROPIC).
Open for enrollment. A second line chemotherapy for metastatic castration-resistant prostate cancer. Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
5. RTOG 0521 A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer.
Enrollment pending. For “high risk” localized prostate cancer. Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
6. RTOG 0621 Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial.
Enrollment pending. For high risk prostate cancer (high Gleason with extracapsular or seminal vesicle margins) patients after prostatectomy. Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
7. RTOG 0622: A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer after Radical Prostatectomy.
Enrollment pending. For very high risk prostate cancer patients with rising PSA after prostatectomy (non-metastatic). Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
8. SWOG S0421 Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo. For Patients with Advanced Hormone-Refractory Prostate Cancer.
Enrollment pending. Metastatic hormone-refractory prostate cancer – First line chemo. Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
9. A Phase III, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients (AstraZeneca).
Enrollment pending. Non-metastatic hormone-refractory prostate cancer (prior Casodex acceptable). Please call Kathryn Morrow, RN, Clinical Coordinator 504-988-6736.
Douglas Slakey, M.D.
1. Effect of Cold Preservation and Hyperbaric Oxygen on Transplant Organ Function.
|
|
 |
|
